IGM Biosciences 관리

관리 기준 확인 2/4

IGM Biosciences CEO는 Mary Harler, Oct2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 € 2.95M 가치에 해당하는 회사 주식의 0.59% 직접 소유합니다. 2.95M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 6 년입니다.

주요 정보

Mary Harler

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.6%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

CEO

Mary Harler (59 yo)

less than a year

테뉴어

Ms. Mary Beth Harler, M.D. is the Chief Executive Officer of IGM Biosciences, Inc. since October 01, 2024 and serves as its Director. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. s...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mary Harler	CEO & Director	less than a year	데이터 없음	0.59% € 3.0m
Misbah Tahir	Chief Financial Officer	5.8yrs	US$1.08m	0.035% € 177.5k
TS Harigopal	Senior Vice President of Group Operations	1.8yrs	데이터 없음	데이터 없음
Steven Weber	Senior VP	2.7yrs	데이터 없음	0.0043% € 21.8k
Paul Graffagnino	Senior Vice President of Legal Affairs	3.8yrs	데이터 없음	데이터 없음
Suzette Tauber	Chief Human Resources Officer	5.4yrs	데이터 없음	데이터 없음
Angus Sinclair	Executive Vice President of Research	3.3yrs	데이터 없음	데이터 없음
Lisa Decker	Chief Business Officer	3.7yrs	US$4.92m	0.030% € 152.6k
Marvin Peterson	Executive Vice President of Process Development & Manufacturing	3.6yrs	데이터 없음	데이터 없음
Elizabeth Haanes	Senior Vice President of Intellectual Property	2.6yrs	데이터 없음	데이터 없음
Elaine Sapinoso	Senior Vice President of Quality	1.8yrs	데이터 없음	데이터 없음
Faraz Siddiqui	Senior Vice President of Manufacturing Operations	1.3yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 1K0 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mary Harler	CEO & Director	no data	데이터 없음	0.59% € 3.0m
Felix Baker	Independent Director	3.8yrs	US$168.55k	0.0037% € 18.8k
M. Behrens	Independent Director	5.8yrs	US$178.30k	0.68% € 3.4m
Mark Davis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Rafi Ahmed	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Lee	Independent Director	5.3yrs	US$166.09k	0.016% € 79.0k
Jakob Topsoe	Independent Director	6.3yrs	US$166.09k	0.15% € 748.1k
Julie Hambleton	Independent Director	6.3yrs	US$204.09k	0.0034% € 16.9k
Christina Topsoe	Independent Director	6.3yrs	US$175.84k	0.099% € 497.9k
William Strohl	Independent Director	6.3yrs	US$236.59k	0% € 0
Elizabeth Thompson	Independent Director	1.1yrs	US$167.54k	0.0073% € 36.9k
Gordon J. Freeman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 1K0 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

IGM Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold €82k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Announces Board Changes

CEO, President & Director recently sold €221k worth of stock

Recent updates

Third quarter 2024 earnings released: US$1.01 loss per share (vs US$1.04 loss in 3Q 2023)

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

Second quarter 2024 earnings released: US$0.79 loss per share (vs US$1.43 loss in 2Q 2023)

IGM Biosciences, Inc. Provides Pipeline Updates

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold €82k worth of stock

Full year 2023 earnings released: US$4.71 loss per share (vs US$5.32 loss in FY 2022)

Insufficient new directors

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.32 loss in 3Q 2022)

IGM Biosciences, Inc. Announces Board Changes

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

CEO, President & Director recently sold €221k worth of stock

Independent Director recently bought €1.0m worth of stock

Insufficient new directors

Independent Director recently bought €1.0m worth of stock

Independent Chairman of the Board recently bought €145k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought €224k worth of stock

Independent Director recently bought €1.3m worth of stock

IGM Biosciences, Inc. Advances Novel Antibody IGM-6268 into Clinical Trials for the Treatment and Prevention of COVID-19

IGM Biosciences, Inc. Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19

IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer

New 90-day high: €94.00

Independent Director has left the company

IGM Biosciences, Inc. Announces Board Changes

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Independent Director recently bought €3.3m worth of stock

New 90-day high: €88.50

IGM Biosciences, Inc. Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma

IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

IGM Biosciences, Inc. Initiates First-In-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’S Lymphoma

AbCellera Biologics Inc. and IGM Biosciences, Inc. Announce Multi-Year Antibody Discovery Collaboration

New 90-day high: €69.50

Independent Director recently bought €1.5m worth of stock

New 90-day low - €41.00

New 90-day low - €45.60

IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from Russell 3000 Value Index

IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from Russell Microcap Value Index

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령